Replies to post #19755 on Marker Therapeutics Inc (MRKR)

[Burrhead1]

I know........that what the article said......excerpt below.....

The phase II, double-blind, randomized trial will evaluate vaccination with folate receptor alpha (FRa) peptide vaccine with GM-CSF as adjuvant therapy following oral cyclophosphamide, compared to GM-CSF/placebo, to prevent recurrence of TNBC. The trial, which is scheduled to open in December 2016, will enroll 280 patients.